Comparison of data between previous study (2002-2005) and current study (2008-2013)
| Parameter | 2002–2005 | 2008–2013 |
|---|---|---|
| Number of cases | 146 | 140 |
| Incidence per 100,000 | 4.9 | 2.9 |
| Age - Median (Range) | 74 (36–93) | 74 (46–98) |
| Histological subtype | ||
| Epithelioid | 34 (23.2%) | 99 (70.7%) |
| Sarcomatoid | 10 (6.8%) | 6 (4.3%) |
| Biphasic | 9 (6.1%) | 15 (10.7%) |
| NOS | 93 (63.7%) | 20 (14.3%) |
| Pleural effusion management | ||
| Pleural effusion present | 110/146 (75.3%) | 117/140 (83.6%) |
| VATS/Thoracoscopic talc | 42/110 (38.1%) | 51/117 (43.6%) |
| IPC | 13/110 (11.8%) | 26 /117 (22.2%) |
| Talc Slurry | 17/110 (15.4%) | 1/117 (0.9%) |
| Oncological treatment | ||
| Port site radiotherapy | 73/122 (59.8%) | 48/76 (63.2%) |
| Chemotherapy (including trial) in all cases | 26/146 (17.8%) | 53/140 (37.9%) |
| Chemotherapy in patients with PS 0–2 | 26/92 (28.2%) | 52/119 (43.7%) |
| Median survival (days) | 267 (95% CI 178–356) | 380 (95% CI 252–397) |